190
Participants
Start Date
October 31, 2024
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2027
Arikayce
Treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin with ARIKAYCE® during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
standard treatment
treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
CHU Amiens-Picardie, Amiens
University Hospital, Angers
OTHER_GOV
Hospital Avicenne
OTHER
University Hospital, Bordeaux
OTHER
University Hospital, Brest
OTHER
CH Compiègne
UNKNOWN
Créteil Hospital
OTHER
Centre Hospitalier Universitaire Dijon
OTHER
University Hospital, Grenoble
OTHER
Centre Hospitalier le Mans
OTHER
Hôpital de la Croix-Rousse
OTHER
APHM - Nord
UNKNOWN
Hôpital Saint Joseph
UNKNOWN
CH Mulhouse
UNKNOWN
CH Orléans
UNKNOWN
Tenon Hospital, Paris
OTHER
Hôpital Necker-Enfants Malades
OTHER
Centre hospitalier de Perpignan
OTHER
Poitiers University Hospital
OTHER
CH Pontoise
UNKNOWN
CHU de Reims
OTHER
Rennes University Hospital
OTHER
CHU de Rouen - Accueil
OTHER
Central Hospital Saint Quentin
OTHER_GOV
IHU Strasbourg
OTHER
University Hospital, Tours
OTHER
CH Abbeville
UNKNOWN
CH Cannes
UNKNOWN
Centre Hospitalier Universitaire, Amiens
OTHER